A leading Covid-19 vaccine under development in China showed inconclusive results about its level of protection, although scientists remain optimistic that the candidate can be among a roster of effective vaccines used to fight the pandemic.
In early-stage clinical trials, Sinovac Biotech Ltd.’s CoronaVac vaccine was shown to induce antibodies in the human body within 28 days of the first immunization, according to results published in the Lancet medical journal this week. The level of antibodies, however, were lower than…